Thalidomide in the treatment of multiple myeloma

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Thalidomide - banned from clinical use in the 1960s because of severe teratogenicity - is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma. Several clinical trials have determined that thalidomide is active in 25-35% of patients with relapsed myeloma. The role of thalidomide in early-stage myeloma is being actively investigated. Thalidomide has antiangiogenic and immunomodulatory properties and is an effective inhibitor of TNF-α. However, the mechanism of its action in myeloma remains unclear. Major toxicities of thalidomide include constipation, sedation, skin rash, fatigue and peripheral neuropathy. This paper summarizes the current status of thalidomide in multiple myeloma.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume1
Issue number1
StatePublished - 2001

Fingerprint

Thalidomide
Multiple Myeloma
Therapeutics
Peripheral Nervous System Diseases
Constipation
Exanthema
Fatigue
Clinical Trials

Keywords

  • Angiogenesis
  • Antiangiogenic therapy
  • bFGF
  • Cancer
  • Multiple myeoma
  • Thalidomide
  • Treatment
  • VEGF

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Thalidomide in the treatment of multiple myeloma. / Rajkumar, S Vincent.

In: Expert Review of Anticancer Therapy, Vol. 1, No. 1, 2001, p. 20-28.

Research output: Contribution to journalArticle

@article{a694f1c9e5bd4d3d96121dd190608d6b,
title = "Thalidomide in the treatment of multiple myeloma",
abstract = "Thalidomide - banned from clinical use in the 1960s because of severe teratogenicity - is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma. Several clinical trials have determined that thalidomide is active in 25-35{\%} of patients with relapsed myeloma. The role of thalidomide in early-stage myeloma is being actively investigated. Thalidomide has antiangiogenic and immunomodulatory properties and is an effective inhibitor of TNF-α. However, the mechanism of its action in myeloma remains unclear. Major toxicities of thalidomide include constipation, sedation, skin rash, fatigue and peripheral neuropathy. This paper summarizes the current status of thalidomide in multiple myeloma.",
keywords = "Angiogenesis, Antiangiogenic therapy, bFGF, Cancer, Multiple myeoma, Thalidomide, Treatment, VEGF",
author = "Rajkumar, {S Vincent}",
year = "2001",
language = "English (US)",
volume = "1",
pages = "20--28",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Thalidomide in the treatment of multiple myeloma

AU - Rajkumar, S Vincent

PY - 2001

Y1 - 2001

N2 - Thalidomide - banned from clinical use in the 1960s because of severe teratogenicity - is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma. Several clinical trials have determined that thalidomide is active in 25-35% of patients with relapsed myeloma. The role of thalidomide in early-stage myeloma is being actively investigated. Thalidomide has antiangiogenic and immunomodulatory properties and is an effective inhibitor of TNF-α. However, the mechanism of its action in myeloma remains unclear. Major toxicities of thalidomide include constipation, sedation, skin rash, fatigue and peripheral neuropathy. This paper summarizes the current status of thalidomide in multiple myeloma.

AB - Thalidomide - banned from clinical use in the 1960s because of severe teratogenicity - is now back in clinical practice as an effective agent in the treatment of relapsed and refractory multiple myeloma. Several clinical trials have determined that thalidomide is active in 25-35% of patients with relapsed myeloma. The role of thalidomide in early-stage myeloma is being actively investigated. Thalidomide has antiangiogenic and immunomodulatory properties and is an effective inhibitor of TNF-α. However, the mechanism of its action in myeloma remains unclear. Major toxicities of thalidomide include constipation, sedation, skin rash, fatigue and peripheral neuropathy. This paper summarizes the current status of thalidomide in multiple myeloma.

KW - Angiogenesis

KW - Antiangiogenic therapy

KW - bFGF

KW - Cancer

KW - Multiple myeoma

KW - Thalidomide

KW - Treatment

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0035557940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035557940&partnerID=8YFLogxK

M3 - Article

C2 - 12113124

AN - SCOPUS:0035557940

VL - 1

SP - 20

EP - 28

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -